Cell News and Research

RSS

Positive interim results from CTI's OPAXIO-TMZ phase II trial on malignant brain tumors presented at ASCO

Cell Therapeutics, Inc. announced encouraging interim results of a phase II clinical study of OPAXIO combined with temozolomide and radiotherapy in patients with newly diagnosed high-grade malignant brain tumors.

6 Jun 2011

Interim results from CTI, Chroma Therapeutics' tosedostat phase II trial on AML presented at ASCO

Cell Therapeutics, Inc. and Chroma Therapeutics Ltd. announced that interim results from the phase II OPAL study of tosedostat in elderly patients with relapsed or refractory acute myeloid leukemia (AML) were presented by Jorge Cortes, M.D. and discussed at the 2011 Annual Meeting of the American Society of Clinical Oncology (ASCO) by Farhad Ravandi, M.D., who presided over the ASCO discussion session, both of the University of Texas M.D. Anderson Cancer Center.

6 Jun 2011

New targeted therapy may halt tumor growth in men with advanced prostate cancer

A new targeted therapy for prostate cancer halts tumor growth in animals with advanced prostate cancer that is resistant to hormone therapy, a new study finds. The results will be presented Saturday at The Endocrine Society's 93rd Annual Meeting in Boston.

6 Jun 2011

Genentech's Avastin, chemotherapy Phase III combination study data on ovarian cancer presented at ASCO

Genentech, a member of the Roche Group, today announced results from OCEANS, a Phase III study evaluating Avastin (bevacizumab) in combination with chemotherapy followed by the continued use of Avastin alone in women with previously treated (recurrent) platinum-sensitive ovarian cancer.

6 Jun 2011

Synta presents ganetespib Phase 2 trial results in advanced non-small cell lung cancer at ASCO 2011

Synta Pharmaceuticals Corp. today presented results at the Annual Meeting of the American Society for Clinical Oncology (ASCO) from a Phase 2 single agent clinical trial of ganetespib in advanced non-small cell lung cancer (NSCLC) that showed promising clinical activity in patients with progressive disease.

6 Jun 2011

New data from Argos AGS-003, sunitinib Phase 2 combination study on RCC presented at ASCO

Argos Therapeutics today announced that new data from its Phase 2 combination study of its Arcelis immunotherapy for the treatment of renal cell carcinoma (RCC), AGS-003, in combination with sunitinib showed improvement over expectations for sunitinib alone in progression-free survival (PFS) in newly diagnosed metastatic RCC patients with unfavorable prognosis.

6 Jun 2011

Super microscopes help scientists identify exact molecular 'switch' that spurs T-cells into action

Using the only microscope of its kind in Australia, medical scientists have been able for the first time to see the inner workings of T-cells, the front-line troops that alert our immune system to go on the defensive against germs and other invaders in our bloodstream.

6 Jun 2011

ImmunoGen's IMGN901 Phase I trial data on multiple myeloma presented at ASCO 2011

ImmunoGen, Inc., a biotechnology company that develops targeted antibody-based anticancer products using its antibody expertise and Targeted Antibody Payload (TAP) technology, today announced positive clinical data with the Company's IMGN901 (lorvotuzumab mertansine) product candidate as featured in an oral presentation at the ASCO 2011 Annual Meeting in Chicago.

6 Jun 2011

Incyte's ruxolitinib Phase III trial data on myelofibrosis presented at ASCO 2011

Incyte Corporation announced today results from the global, pivotal Phase III clinical program of ruxolitinib in patients with myelofibrosis (MF) at the 2011 American Society of Clinical Oncology (ASCO) Annual Meeting.

6 Jun 2011

Bristol-Myers Squibb's second YERVOY Phase 3 trial on metastatic melanoma meets primary endpoint

Bristol-Myers Squibb Company today announced results from a second Phase 3 randomized, double blind study demonstrating that YERVOY (ipilimumab) prolonged the lives of patients with metastatic melanoma.

6 Jun 2011

Promising results from Exelixis' cabozantinib phase 2 trial against metastatic ovarian cancer

Exelixis, Inc. reported longer follow-up data from a fully enrolled cohort of patients with advanced epithelial ovarian cancer, primary peritoneal carcinoma, or fallopian tube carcinoma treated with cabozantinib (XL184) in an ongoing phase 2 adaptive randomized discontinuation trial. Cabozantinib shows promising activity in these patients independent of prior response to platinum-based therapies.

6 Jun 2011

ImmunoGen's SAR3419 Phase I trial data on B-cell non-Hodgkin's lymphoma presented at ASCO 2011

ImmunoGen, Inc., a biotechnology company that develops targeted antibody-based anticancer products using its antibody expertise and Targeted Antibody Payload (TAP) technology, today announced the presentation of favorable clinical data for SAR3419 in the treatment of B-cell non-Hodgkin's lymphoma (NHL).

6 Jun 2011

Alnylam's ALN-VSP Phase I trial data on liver cancer presented at ASCO 2011

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today the results from its Phase I clinical trial with ALN-VSP, a systemically delivered RNAi therapeutic for the treatment of advanced solid tumors with liver involvement.

6 Jun 2011

Positive results from Plexxikon's vemurafenib Phase 2 and 3 trial against metastatic melanoma

Plexxikon Inc., a member of the Daiichi Sankyo Group, today announced efficacy and safety data from the BRIM3 trial, a large, randomized, multi-center Phase 3 clinical study of vemurafenib in patients with previously untreated metastatic melanoma with the BRAFV600 mutation.

6 Jun 2011

New understanding of muscle growth and repair

Revealing another part of the story of muscle development, Johns Hopkins researchers have shown how the cytoskeleton from one muscle cell builds finger-like projections that invade into another muscle cell’s territory, eventually forcing the cells to combine.

5 Jun 2011

New skin cancer drug brings hope

A new drug for the dreaded cancer melanoma is in the horizon. It is called Vemurafenib. This is a class of drug that cancer researchers are applauding today at the American Society of Clinical Oncology's annual meeting in Chicago.

5 Jun 2011

Scientists use super microscope to pinpoint body’s immunity ‘switch’

5 Jun 2011

Scientists to reveal latest research breakthroughs at 'Chemistry and Health' conference

To mark the International Year of Chemistry, the 94th Canadian Chemistry Conference and Exhibition will take place at the Palais des congr-s de Montr-al from June 5 to 9, 2011. The gathering is the biggest ever annual event in Canada to focus on science and the practice of chemistry.

4 Jun 2011

DFG to form new collaborative research centers as of 1 July 2011

The Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) will establish 21 new Collaborative Research Centres (CRCs) as of 1 July 2011. This was decided by the relevant Grants Committee at its spring meeting in Bonn.

4 Jun 2011

Scientists find way to protect kidney from cancer drug toxicity

Scientists may have a way to make the powerful cancer drug cisplatin less toxic to the kidneys and more effective against some cancers.

4 Jun 2011

Cell News and Research

Positive interim results from CTI's OPAXIO-TMZ phase II trial on malignant brain tumors presented at ASCO

Interim results from CTI, Chroma Therapeutics' tosedostat phase II trial on AML presented at ASCO

New targeted therapy may halt tumor growth in men with advanced prostate cancer

Genentech's Avastin, chemotherapy Phase III combination study data on ovarian cancer presented at ASCO

Synta presents ganetespib Phase 2 trial results in advanced non-small cell lung cancer at ASCO 2011

New data from Argos AGS-003, sunitinib Phase 2 combination study on RCC presented at ASCO

Super microscopes help scientists identify exact molecular 'switch' that spurs T-cells into action

ImmunoGen's IMGN901 Phase I trial data on multiple myeloma presented at ASCO 2011

Incyte's ruxolitinib Phase III trial data on myelofibrosis presented at ASCO 2011

Bristol-Myers Squibb's second YERVOY Phase 3 trial on metastatic melanoma meets primary endpoint

Promising results from Exelixis' cabozantinib phase 2 trial against metastatic ovarian cancer

ImmunoGen's SAR3419 Phase I trial data on B-cell non-Hodgkin's lymphoma presented at ASCO 2011

Alnylam's ALN-VSP Phase I trial data on liver cancer presented at ASCO 2011

Positive results from Plexxikon's vemurafenib Phase 2 and 3 trial against metastatic melanoma

New understanding of muscle growth and repair

New skin cancer drug brings hope

Scientists use super microscope to pinpoint body’s immunity ‘switch’

Scientists to reveal latest research breakthroughs at 'Chemistry and Health' conference

DFG to form new collaborative research centers as of 1 July 2011

Scientists find way to protect kidney from cancer drug toxicity

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest Life Science News